A Phase II Exploratory Study of Pre-Operative Treatment with Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 03 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018.
- 26 Apr 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
- 24 Apr 2014 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.